{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:03:27Z","timestamp":1761462207808,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.coph.2021.07.006","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T06:06:45Z","timestamp":1628921205000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["When and how to use direct oral anticoagulants in patients with advanced chronic liver disease?"],"prefix":"10.1016","volume":"60","author":[{"given":"Costanza","family":"De Maria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Galante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Fasoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4401-2340","authenticated-orcid":false,"given":"Andrea","family":"De Gottardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.07.006_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.006_sref2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatol Baltim Md"},{"key":"10.1016\/j.coph.2021.07.006_bib3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1537-2995.2006.00891.x","article-title":"Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities","volume":"46","author":"Abdel-Wahab","year":"2006","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.coph.2021.07.006_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1055\/s-0035-1550434","article-title":"Clinical utility of viscoelastic tests of coagulation (TEG\/ROTEM) in patients with liver disease and during liver transplantation","volume":"41","author":"Mallett","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.coph.2021.07.006_bib5","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/j.seminhematol.2013.06.003","article-title":"Hematologic manifestations of liver disease","volume":"50","author":"Marks","year":"2013","journal-title":"Semin Hematol"},{"key":"10.1016\/j.coph.2021.07.006_bib6","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"Afdhal","year":"2008","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.07.006_bib7","first-page":"155","article-title":"Current management of thrombocytopenia in chronic liver disease","volume":"15","author":"Brown","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2021.07.006_bib8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1055\/s-0037-1615651","article-title":"Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease","volume":"85","author":"Van Thiel","year":"2001","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.coph.2021.07.006_sref9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jth.14020","article-title":"Mechanisms of enhanced thrombin-generating capacity in patients with cirrhosis","volume":"16","author":"Lisman","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.coph.2021.07.006_bib10","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1055\/s-0038-1661393","article-title":"Major changes of von Willebrand factor multimer distribution in cirrhotic patients with stable disease or acute decompensation","volume":"118","author":"Palyu","year":"2018","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.coph.2021.07.006_bib11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2004.01.001","article-title":"Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis","volume":"40","author":"Amitrano","year":"2004","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.07.006_bib12","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","article-title":"Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies","volume":"12","author":"Ogren","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coph.2021.07.006_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2021.07.006_bib14","first-page":"CD005134","article-title":"Pentasaccharides for the prevention of venous thromboembolism","volume":"10","author":"Dong","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.07.006_bib15","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.01.265","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"Intagliata","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.07.006_bib16","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","article-title":"Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis","volume":"44","author":"Amitrano","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.coph.2021.07.006_bib17","first-page":"776","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"10.1016\/j.coph.2021.07.006_bib18","first-page":"1465","article-title":"Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis","volume":"32","author":"Rodriguez-Castro","year":"2012","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.coph.2021.07.006_bib19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/cld.333","article-title":"Management of disordered hemostasis and coagulation in patients with cirrhosis","volume":"3","author":"Intagliata","year":"2014","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.coph.2021.07.006_bib20","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.07.006_bib21","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/jth.13000","article-title":"Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study","volume":"13","author":"Shatzel","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.coph.2021.07.006_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/asheducation-2018.1.332","article-title":"\u201cOptimizing quality care for the oral vitamin K antagonists (VKAs)","volume":"2018","author":"Pengo","year":"2018","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.coph.2021.07.006_bib23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2036.2007.03369.x","article-title":"Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease","volume":"26","author":"Tripodi","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.coph.2021.07.006_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.coph.2021.07.006_bib25","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.006_bib26","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.006_bib27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.006_bib28","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.006_bib29","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.006_bib30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.07.006_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.coph.2021.07.006_bib32","article-title":"Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis","volume":"2015","author":"Robertson","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.07.006_bib33","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.12.018","article-title":"Gastrointestinal safety of direct oral anticoagulants: a large population-based study","volume":"152","author":"Abraham","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.07.006_bib34","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.coph.2021.07.006_sref35","first-page":"694","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.coph.2021.07.006_sref36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.12844","article-title":"The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis","volume":"98","author":"Hum","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.coph.2021.07.006_bib37","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2021.07.006_bib38","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00508-018-1351-y","article-title":"Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function","volume":"130","author":"Scheiner","year":"2018","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.coph.2021.07.006_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijcard.2018.01.097","article-title":"Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants","volume":"264","author":"Pastori","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.coph.2021.07.006_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment\u00a0of portal vein thrombosis following danaparoid\u00a0sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol\u00a0Res Off J Jpn Soc Hepatol"},{"key":"10.1016\/j.coph.2021.07.006_bib41","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","article-title":"\u201cRandomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","volume":"113","author":"Hanafy","year":"2019","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.coph.2021.07.006_bib42","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/clc.23196","article-title":"Anticoagulation in chronic kidney disease: from guidelines to clinical practice","volume":"42","author":"Aursulesei","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.coph.2021.07.006_bib43","first-page":"1231","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary","volume":"20","author":"Steffel","year":"2018","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol"},{"key":"10.1016\/j.coph.2021.07.006_bib44","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4383269","article-title":"Direct oral anticoagulants in cirrhotic patients: current evidence and clinical observations","volume":"2019","author":"Elhosseiny","year":"2019","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2021.07.006_sref45","unstructured":"\u201cMulticenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis - Full Text View - ClinicalTrials.gov.\u201d https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02643212 (accessed May 01, 2021)."},{"key":"10.1016\/j.coph.2021.07.006_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197583","article-title":"Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis","volume":"13","author":"Makam","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.07.006_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.chest.2017.02.009","article-title":"Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies, and\u00a0outcomes from a multicenter observational study","volume":"152","author":"Xu","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.coph.2021.07.006_bib48","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40265-018-0940-4","article-title":"Andexanet\u00a0alfa: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.coph.2021.07.006_bib49","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J\u00a0Thromb Haemost"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:54:35Z","timestamp":1761461675000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":49,"alternative-id":["S1471489221000990"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.07.006","relation":{},"ISSN":["1471-4892"],"issn-type":[{"type":"print","value":"1471-4892"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When and how to use direct oral anticoagulants in patients with advanced chronic liver disease?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}